LTR Pharma Executive Chairman, Lee Rodne, speaks to OnMarket about the Company’s Initial Public Offer (IPO) for a proposed listing on the Australian Securities Exchange (ASX) under ticker code $LTP, and commercialisation plans for SPONTAN®, an innovative intranasal spray treatment for Erectile Dysfunction (ED).